Finance analyst: Novo's sales from obesity drugs may grow earlier than anticipated

Novo Nordisk may see accelerated sales of obesity drugs sooner than expected, thinks Danish bank analyst, who sees great potential in upcoming new data for semaglutide as an obesity treatment.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Preliminary data from a crucial trial concerning a Novo Nordisk obesity drug may accelerate sales in 2023, according to Danish newspaper Børsen in reference to an analysis from Danish bank and financial analyst Nordea.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading